Purple Biotech Reports Potential Biomarker Data Support CM24

REHOVOT, Israel, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today reported new biomarker data for its lead oncology drug, CM24, a first-in-class anti-CEACAM1 monoclonal antibody. Data were presented at the American Association for Cancer Research (AACR) Special Co

Related Keywords

Boston , Massachusetts , United States , Rehovot , Hamerkaz , Israel , American , Gil Efron , Hadas Reuveni , Drug Administration , American Association For Cancer Research , Purple Biotech Ltd , Exchange Commission , Bristol Myers Squibb , American Association , Cancer Research , Special Conference , Pancreatic Cancer , Advanced Pancreatic Cancer , Exploratory Biomarkers , Neutrophil Extracellular Traps , Purple Biotech , Bristol Myers Squib , Tumor Associated Antigen , Looking Statements , Safe Harbor , Private Securities Litigation Reform Act , Annual Report , Registration Statements , Tumor Microenvironment , Immune Evasion , The Company , Pancreatic Cancer Patients , Tumor Infiltrating Lymphocytes , Company , Eacam1 , Chemotherapy , Tumor Cells ,